Preclinical Abuse Potential Assessment

Area of Science:

• Pharmacology
• Neuroscience
• Drug Development

Background:

• Preclinical evaluation of drug abuse potential is increasingly critical for new drug applications.
• Existing laboratory evaluations for abused drugs have a long history.
• A unified approach to preclinical drug abuse testing is needed.

Purpose of the Study:

• To outline a unified testing strategy for preclinical evaluation of new drug abuse potential.
• To detail core preclinical studies required for drug scheduling recommendations.
• To guide the selection of parameters for these evaluations.

Main Methods:

• Focus on dependence/withdrawal studies.
• Assessment of drug discriminative cue.
• Evaluation of drug self-administration.
• Consideration of preclinical species, doses, conditions, routes, comparators, and behavioral designs.

Main Results:

• Discussion centers on Food and Drug Administration (FDA) requirements for drug scheduling.
• Provides guidance on conducting evaluations for abuse potential.
• Highlights key parameters for study design.

Conclusions:

• A standardized preclinical testing framework is vital for accurate abuse potential assessment.
• This framework supports informed FDA drug scheduling decisions.
• Methodological consistency ensures reliable data for regulatory review.